Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 23, 2020 08:00 ET | Source: TeneoBio, Inc

Teneobio Announces Poseida’s Exercise of Four Commercial License Options for UniDabs to Targets for Advanced CAR T-cell Therapies

NEWARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage next generation, multi-specific antibody therapeutics company, announced today that in 2020, Poseida exercised four...
November 16, 2020 11:00 ET | Source: TeneoBio, Inc

TeneoFour’s CD38 Inhibitor Rejuvenates Energy Metabolism of Aged Animals

NEWARK, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoFour, Inc. announced today a Nature Metabolism publication...
October 21, 2020 08:00 ET | Source: TeneoBio, Inc

Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio

NEWARK, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, today announced that it has...
November 06, 2019 08:00 ET | Source: TeneoBio, Inc

Teneobio’s Lead Candidate, TNB-383B, Receives Orphan Drug Designation from the FDA for the Treatment of Multiple Myeloma

NEWARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
January 08, 2018 08:00 ET | Source: TeneoBio, Inc

Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific Antibodies

MENLO PARK, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Teneobio, Inc., a next generation multi-specific antibody therapeutics company announced today the initiation of a research collaboration and...
May 22, 2017 08:00 ET | Source: TeneoBio, Inc

Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy

MENLO PARK, Calif. and SAN DIEGO, May 22, 2017 (GLOBE NEWSWIRE) -- Teneobio, Inc. and Poseida Therapeutics, Inc. today announced that they have entered a commercial license agreement for the use of...